E2F

Caris Life Sciences to Present Research at the 2024 ASCO Genitourinary Cancers Symposium

Retrieved on: 
Tuesday, January 23, 2024
Neutrophil, PST, Research, Overalls, Prostate cancer, Androgen receptor, University, Cancer, NCI, Prognosis, Metastasis, FACP, Transcriptome, MHC, Abstract, Diagnosis, Medicine, MYC, NK, Neoplasm, MAPK, DNA, Survival, HSD3B1, Disease, Drug development, ADT, E2F, Liver, PIM, Urachal cancer, Lung, POA, Physician, Renal cell carcinoma, PCA, B cell, Poster, RCC, Escape Room, AI, Immunotherapy, Recurrence, MBA, Prostate, Phenotype, PIM1, Gene expression, IL-6, Huntsman Cancer Institute, Patient, MD, Metadata, ASCO, WSP, C7, Society, PSA, FDA, NEPC, Vaccine

IRVING, Texas, Jan. 23, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, today announced that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present eight studies across four tumor types at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, January 25-27, 2024 in San Francisco. The findings demonstrate the continued and expanded capabilities of Caris' comprehensive multi-modal database to enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment.

Key Points: 
  • That's a major focus of the wide array of research Caris and our POA collaborators will proudly present at this year's ASCO GU."
  • The research is a collaboration with the Huntsman Cancer Institute at the University of Utah and other POA members.
  • Caris will present additional data from studies demonstrating the critical role of comprehensive molecular profiling in the treatment of genitourinary cancers.
  • The POA includes 90 cancer centers, academic institutions, research consortia and healthcare systems, including 42 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research.

CloudBees Announces New Cloud Native DevSecOps Platform

Retrieved on: 
Thursday, September 14, 2023
Software, Technology, Security, GitHub, VSM, Software as a service, OPA, DSL, Feedback, WORLD, E2F, Organization, Investment, Collection, CloudBees, Engineering, FedRAMP, Video game, Sales, Audit, DevOps, Tektōn

DEVOPS WORLD – CloudBees, the leading software delivery platform for enterprises, announced today a new cloud native DevSecOps platform that places platform engineers and developer experience front and center.

Key Points: 
  • DEVOPS WORLD – CloudBees, the leading software delivery platform for enterprises, announced today a new cloud native DevSecOps platform that places platform engineers and developer experience front and center.
  • It also redefines DevSecOps by addressing the challenges associated with delivering better, more secure and compliant cloud native software at a faster pace than ever.
  • With the rush towards cloud native application development, software development and delivery teams struggle with the complexity that comes with modern cloud native architectures.
  • The CloudBees platform empowers organizations to simplify complex cloud native development and deployment processes across all the tools in the DevOps tool chain, thereby accelerating innovation velocity.

Apexigen Completes Business Combination to Become a Publicly Listed Immuno-oncology Company

Retrieved on: 
Monday, August 1, 2022
FC, PIPE, Type, SAN, Cancer, Neoadjuvant therapy, Securities Exchange Act of 1934, Safety, Tumor microenvironment, CD4, Perception, Securities Act of 1933, Acquisition, ASCO, U.S. Securities and Exchange Commission, Annual general meeting, Biomarker, American Society of Clinical Oncology, Lincoln Park, E2F, Nivolumab, ESMO, Cancer Research Institute, Society, Oncogene, Neoplasm, GLOBE, Nasdaq, PD-1, SEC, Pancreatic cancer, Immune system, DLA Piper, CD40, FDA, Therapy, Ovarian cancer, Sarcoma, Congress, Adoption, European Society for Medical Oncology, P.C, Patient, B cell, Wilson Sonsini Goodrich & Rosati, Chemoradiotherapy, Vaccine, Bank, Pharmaceutical industry, Nature Medicine

SAN CARLOS, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced the closing of its previously announced business combination with Brookline Capital Acquisition Corp. (“BCAC”), a special purpose acquisition company. Gross proceeds from this transaction totaled $19.0 million, which included funds held in BCAC’s trust account and a concurrent private placement investment in public equity (“PIPE”) financing. The combined, publicly traded company will operate under the name Apexigen, and its common stock will commence trading on the Nasdaq Capital Market on August 1, 2022, under the ticker symbol “APGN.” Apexigen’s management team will continue leading the combined company.

Key Points: 
  • Today marks an important turning point for Apexigen as we become a publicly listed biopharmaceutical company, poised to provide innovative solutions to overcome outstanding challenges in oncology, said Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer of Apexigen.
  • We believe sotigalimab has the potential to become a backbone of combination therapy to treat patients with cancer.
  • The proceeds from the business combination and PIPE transactions do not include potential proceeds from Lincoln Parks $50.0 million committed equity line.
  • There can be no assurance that future developments affecting the combined company will be those that the parties have anticipated.

Baylor College of Medicine Presents eFFECTOR Therapeutics-Backed Preclinical Data Supporting Development of Zotatifin in Triple-Negative Breast Cancer at 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Thursday, October 7, 2021
NASDAQ, EIF4A, ER, San Francisco, Escape Room, Therapy, Everolimus, Zhao Na, Interferon, Conference, SAN, Department, Syngenic, COVID-19, Breast cancer, Triple-negative breast cancer, MNK, Baylor College of Medicine, University of California, San Francisco, Protein, Survival, NSCLC, GLOBE, Cancer, MTOR, STRI, Effector, KRAS, FDA, 4F, Pfizer, University, TNBC, Toxicity, AACR, Hope, RNA transfection, CEO, Baylor University, DARPA, Pembrolizumab, E2F, Partnership, Patient, Stri Parva, EIF4E, Pharmaceutical industry

SAN DIEGO, Oct. 07, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, in collaboration with investigators at Baylor College of Medicine, today announced the presentation of new positive data for zotatifin in animal models of triple-negative breast cancer (TNBC) at the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Zotatifin is a potent and sequence-selective inhibitor of eukaryotic translation initiation factor 4A (eIF4A) mediated translation.

Key Points: 
  • Zotatifin is a potent and sequence-selective inhibitor of eukaryotic translation initiation factor 4A (eIF4A) mediated translation.
  • In the study, zotatifin treatment slowed tumor growth in six out of eight syngeneic TNBC models without apparent toxicity.
  • We believe zotatifin may have therapeutic benefit in this difficult-to-treat subset of breast cancer patients, particularly in combination with other FDA-approved agents.
  • eFFECTOR is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as STRIs.